As developers of high-complexity biologic cocktails, we read with interest the Feature by Strohbehn et al.1 in the December 2021 issue of Nature Biotechnology voicing concerns about the risk of unjustified patents for arguably obvious drug combinations. The current approach to clinical trial design is built for the development of single-agent therapies; it lacks the scalability needed to systematically explore the entire design space of combination therapies. Full factorial trial designs exploring all possible combinations and dosage levels would be infeasible even for the largest biopharmaceutical companies. Against this backdrop, it is not surprising that drug developers focus their efforts on the much smaller set of obvious combinations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
$99.00
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
References
-
Strohbehn, G. W., Kacew, A. J., Goldstein, D. A., Feldman, R. C. & Ratain, M. J. Nat. Biotechnol. 39, 1504–1510 (2021).
-
Pharmacy Benefits, V. A. Management Services. Ledipasvir/Sofosbuvir (Harvoni®) National Drug Monograph (2014).
-
Shlay, J. C. et al. Terry Beirn Community Programs for Clinical Research on AIDS. J. Am. Med. Assoc. 280, 1590–1595 (1998).
-
Bosch, J. et al. BMJ 324, 699–702 (2002).
-
Wilcox, M. H. et al. N. Engl. J. Med. 376, 305–317 (2017).
-
Mulangu, S. et al. N. Engl. J. Med. 381, 2293–2303 (2019).
-
Muthas, D., Boyer, S. & Hasselgren, C. MedChemComm 4, 1058–1065 (2013).
-
Maddipatla, M. U.S. signs $450 million contract with Regeneron for COVID-19 therapy. Reuters (2020).
-
Abinader, L. G. U. S. Government funding of Lilly’s LY-CoV555 antibody against COVID-19. Knowledge Ecology International (2020); https://www.keionline.org/34308
-
Anonymous. Regeneron enters agreement with BARDA on antibody therapy for Ebola. GEN Biotechnol. https://www.genengnews.com/topics/drug-discovery/regeneron-enters-agreement-with-barda-on-antibody-therapy-for-ebola/ (2015).
-
Box, G. E. P. Improving Almost Anything: Ideas and Essays rev. edn (Wiley-Interscience, 2006).
-
Fisher, R. A. The Design of Experiments (Oliver and Boyd, 1937).
-
CDER & CBER. ICH guidance Q8(R2) Pharmaceutical Development. (2020).
-
CDER & CBER. ICH Guidance Document Q9 Quality Risk Management. (2006).
-
CDER & CBER. ICH Guidance Document Q10 Pharmaceutical Quality System. (2009).
-
Palmer, A. C., Izar, B., Hwangbo, H. & Sorger, P. K. Clin. Cancer Res. 28, 368–377 (2022).
-
Jones, B. & Nachtsheim, C. J. J. Qual. Technol. 43, 1–15 (2011).
-
Jones, B. & Nachtsheim, C. J. J. Qual. Technol. 45, 121–129 (2013).
-
Fisher, R. A. J. Ministry Agric. 33, 503–515 (1926).
-
Chakraborty, B., Collins, L. M., Strecher, V. J. & Murphy, S. A. Stat. Med. 28, 2687–2708 (2009).
-
Jaynes, J., Ding, X., Xu, H., Wong, W. K. & Ho, C.-M. Stat. Med. 32, 307–318 (2013).
-
Huang, H. & Chen, X. Comput. Stat. Data Anal. 157, 107150 (2021).
-
Xiao, Q., Wang, L. & Xu, H. Stat. Med. 38, 236–246 (2019).
-
Abhyankar, M. M. et al. Front. Immunol. 12, 683157 (2021).
-
Zhao, H. et al. Preprint at bioRxiv https://doi.org/10.1101/2021.12.21.473715 (2022).
-
Taylor, P. R. et al. Linxian Nutrition Intervention Trials Study Group. Cancer Res. 54(suppl), 2029s–2031s (1994).
-
Yu, L. X. et al. AAPS J. 16, 771–783 (2014).
-
Scannell, J. W., Blanckley, A., Boldon, H. & Warrington, B. Nat. Rev. Drug Discov. 11, 191–200 (2012).
-
Paul, S. M. et al. Nat. Rev. Drug Discov. 9, 203–214 (2010).
-
Pharma Intelligence. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021); https://pharmaintelligence.informa.com/resources/product-content/2021-clinical-development-success-rates
Ethics declarations
Competing interests
The authors are employees of Lumen Bioscience.
About this article
Cite this article
Dodds, M., Roberts, J. & Finrow, B. Improving combination drug trials using ‘definitive screening designs’.
Nat Biotechnol (2022). https://doi.org/10.1038/s41587-022-01521-w
-
Published:
-
DOI: https://doi.org/10.1038/s41587-022-01521-w
